CSL
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

CSL Limited is a global biotechnology company that develops and manufactures medicines and vaccines for rare and serious diseases, influenza prevention, and iron deficiency and nephrology. The company operates through three main business units: CSL Behring, which produces biotherapies for conditions such as hemophilia, immunodeficiencies, and hereditary angioedema; CSL Seqirus, which provides seasonal and pandemic influenza vaccines using egg, cell, and adjuvant technologies; and CSL Vifor, which focuses on therapies for iron deficiency anemia and kidney disease. CSL Behring includes the subsidiary CSL Plasma, which operates a plasma collection network. The company maintains manufacturing facilities in Australia, Germany, the United States, Switzerland, and the United Kingdom. CSL was established in 1916 and incorporated in 1991.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage csl.com
Sector Healthcare IR page investors.csl.com
Tags
plasma-derived therapies, influenza vaccines, iron deficiency, nephrology, hemophilia, immunodeficiencies, hereditary angioedema, cell-based vaccines, adjuvant technology, rare diseases, CSL Behring, CSL Seqirus, CSL Vifor, CSL Plasma, ALBURUX, MF59
Press page —

Metrics

Valuation  
Market cap A$ 98.156B
Market cap (USD) $ 66.072B
P/E 2,452.19
PEG 539.19
P/BV 343.04
P/S 8.71
P/OCF 34.76
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 14.6%
ROI 14.0%
ROIC 14.0%
Profit margin 18.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 4.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 14.8B 13.31B 10.562B 10.31B 9.151B 8.539B 7.588B 6.616B 5.91B 5.459B 5.335B 4.95B 4.433B 4.188B 4.029B 3.065B
Net profit 2.714B 2.244B 2.255B 2.375B 2.103B 1.919B 1.729B 1.337B 1.242B 1.379B 1.307B 1.216B 982.6M 940.601M 952.119M 759.858M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Update - Notification of buy-back - CSL Bull 1 Bear 0 Capital return
Update - Notification of buy-back - CSL Bull 1 Bear 0 Routine
Update - Notification of buy-back - CSL Bull 1 Bear 0 Routine

Prompts

CSL Limited (ticker CSL), listed in Australia.

Company History

Date Change Detail
Dec 31, 2010 Reporting currency Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding CSL Limited

ETF Weight in ETF Shares Market value As of
UMMA 0.53% 12,810 $ 1.575M Aug 31, 2026
AVSD 0.26% 6,990 $ 949.924K Nov 16, 2026
IVSI 0.22% 216 $ 17.159K Jun 30, 2026
GEW 0.19% 2,226 $ 273.68K Aug 31, 2026
NTSI 0.16% 9,999 $ 794.839K Jun 30, 2026
DFAI 0.11% 150,140 $ 20.913M Nov 12, 2026
AVDE 0.07% 100,501 $ 13.658M Nov 16, 2026
DFSI 0.06% 5,011 $ 697.99K Nov 12, 2026
DFAX 0.03% 28,297 $ 3.942M Nov 12, 2026
DFIC 0.01% 14,617 $ 2.036M Nov 12, 2026